GREVLIMID
Cipla shares surge over 6% post Q4 results. Should you buy or sell?
Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.
Q4 results today: Tata Motors, Cipla among 87 companies to announce earnings
Q4 results today: Several other companies scheduled to release their financial results include Cholamandalam Finance, Eicher Motors, Finolex Industries, Jupiter LifeLine Hospitals, Kalyan Jewellers, Piramal Pharma, Punjab and Sind Bank, Spencers Retail, TCI Express, Thermax, and more.
Cipla Q4 Results Preview: Profit may rise up to 71% YoY on healthy operations
Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by as much as 71% year-on-year, alongside an expected 7% year-on-year increase in net sales.
Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?
Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North America as well as emerging markets. DRL’s revenue also increased 12% YoY to Rs 7,083 crore.
Dr Reddy's Q4 Preview: PAT may rise over 50% YoY on strong US sales
Based on an average estimate from four brokerages, revenue from operations during the January-March 2023 period is anticipated to increase by up to 18% year-on-year. Concurrently, the net profit after tax is expected to experience a robust surge of up to 54% year-on-year.
Hot Stocks: Brokerages on RIL, Entero Healthcare, Natco Pharma and Persistent Systems
Brokerage Nomura upheld a neutral rating on Persistent Systems, while Investec continues to advocate a buy stance on Natco Pharma and has initiated a buy recommendation on Entero Healthcare. Conversely, CLSA has downgraded RIL to an outperform rating.
- Go To Page 1
Hot Stocks: Brokerages view on Avenue Supermarts, Bajaj Finance, ICICI Bank and Sun Pharma
Brokerage firm HSBC maintained a buy rating on Sun Pharma, Citigroup recommended a buy rating on ICICI Bank, JPMorgan has an overweight rating on Bajaj Finance and CLSA recommended a buy rating on Avenue Supermarts.
Stocks to buy: Will pharma scrips keep rising? 3 stocks with potential upside of up to 30.6%
In the December 2023 quarter, the pharma stock universe (89 stocks) reported 12% and 27% y-o-y growth in revenue and PAT, respectively. Comparatively, the aggregate revenue and PAT of Nifty 500 companies (excluding pharma) grew by 5.3% and 20%, respectively. The sector fundamentals are stable, but stretched valuations could hinder price performance.
Sun Pharma's steady Q3 earnings prompt target upgrades by brokerages. Should you buy?
The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price.
Dr Reddy's shares rise 4% on Q3 PAT jump but brokerages remain unmoved. Here's why
The drug maker on Tuesday reported an 11% year-on-year (YoY) jump in net profit at Rs 1,379 crore for the quarter ended December 31, 2023, as against Rs 1,247 crore a year ago. The company said the net profit was led by new products and base business market share gain in the US, and also new launches and strong volumes in Europe. The Hyderabad-based firm's revenue rose 7% at Rs 7,215 crore as against Rs 6,770 crore crore in the year-ago period.
Sun Pharma Q3 preview: Consolidated PAT may rise 8% YoY amid moderate revenue growth
Sun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and India. Analysts predict a nearly 8% YoY growth in consolidated net profit to Rs 2,329 crore. Consolidated revenue is estimated to rise 9% YoY to Rs 12,265.40 crore.
Dr Reddy’s Q3 Results Preview: Profit may drop on lower Revlimid sales, higher costs
The drugmaker is expected to report a 1.1% YoY drop in consolidated net profit to Rs 1,247 crore, according to the average of estimates given by seven brokerages. The company is scheduled to release its quarterly earnings on Tuesday.
Hot Stocks: Brokerages on Zydus Life, Hindalco, Anupam Rasayan and Alkem Laboratories
Macquarie maintained an underperform rating on Zydus Life with a target price of Rs 490. The Q2FY24 results were a mixed bag.
Cipla slumps nearly 8% after USFDA warning letter for manufacturing lapses
After an inspection at the Pithampur plant, the USFDA issued a warning letter stating that the company's methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to good manufacturing practices, and that its drug products are adulterated.
Pharma Q2 Preview: Cipla to see steady quarter; higher profit and revenue growth for Dr Reddy's
Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three brokerages, and net profit for the same period is expected to rise around 19% YoY.
Motilal Oswal Financial Services neutral on Dr. Reddy's Laboratories; target price: Rs 5240
Dr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 94235.44 Crore) operating in Pharmaceuticals sector.
Buy Cipla, target price Rs 1420: Motilal Oswal Financial Services
The brokerage values CIPLA at 25x 12Mforward earnings and add NPV of INR30 related to g-Revlimid to arrive at its TPof INR1,420.
Outlook on healthcare sector; Sun Pharma, Granules could give 18-20% return in 12 months
The YoY growth of both Indian pharma companies and MNCs experienced a revival in July ’23. Indian pharma companies grew 7% YoY, while MNC pharma grew at a modest rate of 5% YoY in July ’23. Growth was majorly driven by price hikes.
Zydus Lifesciences Q1 Results: Profit more than doubles on US sales growth
Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.
Hot Stocks: Brokerages on Cipla, Axis Bank, Dr Reddy’s, Tech Mahindra and Colgate
Jefferies upgraded Cipla to buy with a target price of Rs 1210. The US performance leads to the beat in Q1 results. The management commentary provides a positive read-through.
Q1 Results Preview: What's in store for Tech Mahindra, Dr Reddy's, Cipla, Tata Consumer, BPCL, PNB
Following its IT peers, Tech Mahindra is expected to see a muted quarter with sequential decline in communications revenue and flat growth in the enterprise segment
Motilal Oswal Financial Services neutral on Dr. Reddy's Laboratories, target price: Rs 4680
Dr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 83241.46 Crore) operating in Pharmaceuticals sector.
4 reasons Sun Pharma is this week's stock pick
Sun Pharma’s 2022 annual report estimates that the global pharmaceutical market will grow by $400 billion between 2021 and 2026.
Sun facing some clouds is still a buy for analysts
Shares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% from the previous close. More than 5.6 million shares exchanged hands on the BSE and NSE on Monday, over twice its combined average daily volume for the last month.
Hold Dr. Reddy's Laboratories, target price Rs 5100: Sharekhan by BNP Paribas
Dr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 73305.57 Crore) operating in Pharmaceuticals sector.
Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommend
Dr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Thursday's trade. While its revenue from operations increased by 15.28% YoY to Rs 5,843 crore, total expenses were down 4% at Rs 5,132.2 crore. US revenues fell 17% QoQ. Jefferies maintained its Buy rating on Dr Reddy’s Laboratories with a target price of Rs 5,650, while Prabhudas Lilladher downgraded the stock to Reduce with a revised target price of Rs 4,500 from Rs 4,900.
Hot Stocks: Brokerages on TCS, Sun Pharma, HPCL, ONGC and Oil India
JPMorgan maintained an underweight rating on TCS with a target price of Rs 2700. TCS Q4 missed expectations across the board led by US weakness.
Buy Zydus Lifesciences, target price Rs 572: Sharekhan by BNP Paribas
Zydus Lifesciences, incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 48616.16 Crore) operating in Pharmaceuticals sector.
Load More
